📈 Jumpstart Signal Watchlist — September 01, 2026

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $14.19 is 5% below 3yr high $14.97 · ⏳ SMA200 $9.61 (current price $14.19 is above) · 💰 Market Cap $1.3B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.5%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ MeiraGTx Reports Second Quarter 2026 Financial and Operational Results — GlobeNewswire.
🤖 MeiraGTx reported strong Q2 2026 results, including a large year-over-year swing to net income and a notable revenue increase. The update also highlighted FDA breakthrough designation, positive clinical data, and a balance-sheet boost from financing and asset acquisition activity.
✅ RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating — MT Newswires.
🤖 RBC raised its price target on MGTX and kept an Outperform rating, which is typically supportive for the stock. The higher target suggests improving analyst confidence after the company’s recent operational update.
⚪️ MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Yahoo Finance / GlobeNewswire.
🤖 The company disclosed an inducement equity grant to a new employee. This is routine corporate compensation news and does not materially change the near-term investment case.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: BioCryst Pharmaceuticals is a biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its key products include ORLADEYO for preventing HAE attacks and RAPIVAB for treating influenza, and it is also advancing additional rare-disease drug candidates.
- 🎯 Current $9.92 is 11% below 3yr high $11.19 · ⏳ SMA200 $8.51 (current price $9.92 is above) · 💰 Market Cap $2.5B
- BCRX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 26/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1400% (>20%); Revenue growth 34% (>15%).
⏰ Entry (E): 6/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ BioCryst Reports Second Quarter 2026 Financial Results — GlobeNewswire.
🤖 BioCryst beat Q2 expectations, raised total revenue guidance, and reported commercial progress with ORLADEYO oral pellets and navenibart enrollment. These developments are favorable for BCRX because they improve near-term financial visibility and highlight pipeline momentum.
✅ BioCryst is profitable. Now it wants to buy more rare disease drugs — CNBC.
🤖 This article highlights BioCryst’s profitability and cash-generating position, which could support future acquisitions and growth strategy. That is generally positive for BCRX because it suggests more flexibility to expand beyond its current asset base.
⚪️ Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price — MarketBeat.
🤖 RBC lowered its price target while keeping an outperform rating, which is a mixed signal rather than a clear downgrade. The article also notes BioCryst’s strong Q2 beat, so the overall impact on BCRX is balanced.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $21.88 is 5% below 3yr high $23.04 · ⏳ SMA200 $15.56 (current price $21.88 is above) · 💰 Market Cap $600M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 2/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Ooma Q2 FY2027 slides: business growth accelerates to 38% — Investing.com.
🤖 Ooma’s fiscal second-quarter update showed strong business growth, improved profitability, and a raised full-year outlook. The market reacted positively, with the stock rising in after-hours trading after the release.
✅ Ooma shares rise on Q2 earnings beat and upbeat guidance — Investing.com.
🤖 Ooma beat analyst expectations on both earnings and revenue and guided above consensus for the full year. Strong growth in subscription revenue and EBITDA supported a positive stock reaction.
✅ Ooma Reports Fiscal Second Quarter 2027 Financial Results — Yahoo Finance / Business Wire.
🤖 The company reported 25% revenue growth, higher net income, and stronger adjusted earnings for the quarter. The release also highlighted business growth tied to recent acquisitions, which is favorable for the stock.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: HealthStream provides software and online services for healthcare organizations to manage workforce learning, training, credentialing, competency, and scheduling. Its tools help hospitals and other care providers develop staff and support compliance and performance management.
- 🎯 Current $29.67 is 13% below 3yr high $34.07 · ⏳ SMA200 $24.02 (current price $29.67 is above) · 💰 Market Cap $868M
- HSTM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (11.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 28% (>20%); Low LT D/E 0.08 (<1.0); PEG ratio 1.48 (<1.5).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ HealthStream Announces Second Quarter 2026 Results — Business Wire.
🤖 HealthStream reported record quarterly revenue of $83.7 million, with EPS of $0.23 and adjusted EBITDA of $20.6 million both improving year over year. The company also raised full-year revenue and EBITDA guidance, which is favorable for the stock despite a lower net income outlook from higher investment spending.
✅ HealthStream Inc (HSTM) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Wins — GuruFocus News.
🤖 The article highlights record revenue and improved profitability in Q2 2026, reinforcing the upbeat earnings backdrop for HSTM. It points to strong operational performance and strategic momentum, both of which are typically supportive for the shares.
⚪️ HealthStream declares $0.035 dividend (HSTM:NASDAQ) — Seeking Alpha.
🤖 The dividend declaration is routine and broadly in line with the prior payout, so it does not materially change the investment outlook. It may support shareholder returns, but it is not a major catalyst for the stock.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $56.89 is 0% below 3yr high $57.10 · ⏳ SMA200 $47.25 (current price $56.89 is above) · 💰 Market Cap $14.2B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 4/10
- 🗞️ News sentiment is negative (mixed coverage).
✅ BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL — MarketBeat.
🤖 The article reports a large new BlackRock stake and notes Exelixis still traded near its 52-week high after solid quarterly results. Institutional buying and resilient stock performance are modestly positive signals for sentiment.
❌ Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot — Yahoo Finance.
🤖 The article says Exelixis lowered its 2026 revenue outlook to $2.50 billion–$2.55 billion while investing more heavily in its oncology pipeline. Lower guidance and the stock drop are negative for near-term sentiment despite strong Q2 results.
❌ Exelixis Q2 2026 slides: strong earnings, but NET slowdown cuts guidance — Investing.com.
🤖 The article emphasizes that Exelixis beat EPS estimates but missed revenue expectations and reduced full-year revenue guidance by about $50 million at the midpoint. The guidance cut and the after-hours share decline are negative for the stock.
⚪️ Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 This recap highlights strong Q2 revenue and profit, but it is mainly a summary of the company’s quarterly results and does not add a major new catalyst beyond the earnings release. The mixed earnings and guidance context makes it broadly neutral to slightly negative.
⚪️ Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition — Yahoo Finance.
🤖 This piece appears to be a background story about ownership and the company’s strategic transition rather than a fresh operating update. It does not provide a clear new fundamental catalyst, so the impact is neutral.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $56.54 is 2% below 3yr high $57.72 · ⏳ SMA200 $50.63 (current price $56.54 is above) · 💰 Market Cap $11.0B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 167% (>20%); Revenue growth 27% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Public Employees Retirement System of Ohio Invests $14.27 Million in American Healthcare REIT, Inc. $AHR — MarketBeat.
🤖 This is positive because it highlights institutional buying and repeats that analysts remain broadly constructive on AHR, with a Moderate Buy consensus and a $61.25 average target. It also cites recent bullish analyst actions from Truist and RBC, which can support sentiment toward the stock.
✅ American Healthcare REIT, Inc. $AHR Shares Bought by Wellington Management Group LLP — MarketBeat.
🤖 This is positive because Wellington Management increased its stake in AHR, signaling institutional confidence. The article also references AHR's earnings beat and raised 2026 guidance, both supportive for the stock.
✅ 1495661 Shares in American Healthcare REIT, Inc. $AHR Acquired by Bank of New York Mellon Corp — MarketBeat.
🤖 This is positive because it reports a new large institutional position in AHR, which can be read as a vote of confidence in the company. The article also notes the company’s recent earnings beat, reinforcing a favorable backdrop.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: ADM (Archer Daniels Midland Company) is a global agricultural processing and nutrition company that purchases crops from farmers, transports them through its logistics network, and transforms them into food, animal feed, industrial, and biofuel products.
- 🎯 Current $84.55 is 3% below 3yr high $87.32 · ⏳ SMA200 $71.38 (current price $84.55 is above) · 💰 Market Cap $41.0B
- ADM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Base breakout (range: 7.7%); Low drawdown (12.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 316% (>20%); Low LT D/E 0.32 (<1.0).
⏰ Entry (E): 2/20
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Archer-Daniels-Midland (ADM) Beat Q2 Estimates, Is It Still Slightly Overvalued? — Yahoo Finance.
🤖 The article says ADM beat analyst expectations on revenue, EPS, and gross margin, which is supportive for the stock. It also notes the shares had strong year-to-date momentum, though it questions valuation.
✅ ADM Q2 2026 slides: profit surges 75%, guidance raised on crush strength — Investing.com.
🤖 ADM reported a sharp year-over-year increase in segment operating profit and raised full-year EPS guidance. The combination of stronger-than-expected results and higher outlook is favorable for the stock.
✅ ADM Raises 2026 EPS View: Can Biofuel Strength Sustain Growth? — Yahoo Finance.
🤖 This piece highlights ADM’s raised 2026 EPS outlook after a strong second quarter. Higher guidance and continued biofuel strength are positive signals for earnings expectations.
🍭 Bonus (B): 0/10 — Food & Kindred Products